HC Wainwright Increases TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $12.00

TriSalus Life Sciences (NASDAQ:TLSI) had its target price increased by equities research analysts at HC Wainwright from $11.00 to $12.00 in a research report issued on Wednesday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 143.41% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Zacks Research raised shares of TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Finally, Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.00.

TriSalus Life Sciences Trading Down 1.0%

TriSalus Life Sciences stock opened at $4.93 on Wednesday. The company has a market cap of $303.59 million, a price-to-earnings ratio of -3.79 and a beta of 0.44. The firm has a 50-day moving average of $4.88 and a 200-day moving average of $4.31. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. TriSalus Life Sciences has a one year low of $2.20 and a one year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million. On average, equities analysts expect that TriSalus Life Sciences will post -0.31 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of TLSI. Bank of America Corp DE lifted its stake in shares of TriSalus Life Sciences by 1.9% during the 1st quarter. Bank of America Corp DE now owns 201,719 shares of the company’s stock worth $807,000 after buying an additional 3,703 shares during the last quarter. Cura Wealth Advisors LLC acquired a new position in TriSalus Life Sciences in the 2nd quarter valued at $36,000. Renaissance Technologies LLC acquired a new stake in shares of TriSalus Life Sciences during the first quarter worth $124,000. Deutsche Bank AG bought a new position in TriSalus Life Sciences during the second quarter worth about $221,000. Finally, Corient Private Wealth LP boosted its holdings in TriSalus Life Sciences by 61.7% in the 2nd quarter. Corient Private Wealth LP now owns 147,152 shares of the company’s stock valued at $670,000 after purchasing an additional 56,152 shares during the period. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.